Prelabeling of chimeric monoclonal antibody L6 with90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy

Min Li; Claude F. Meares; Qansy Salako; David L. Kukis; Gao Ren Zhong; Laird Miers; Sally J. DeNardo

Prelabeling of chimeric monoclonal antibody L6 with⁹⁰yttrium- and ¹¹¹indium-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy

Min Li, Claude F. Meares, Qansy Salako, David L. Kukis, Gao Ren Zhong, Laird Miers, Sally J. DeNardo

Chemistry

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

⁹⁰Y and ¹¹¹In have been attached to chimeric monoclonal antibody L6 with a bifunctional chelating agent (DOTA-peptide isothiocyanate). The bifunctional chelating agent was prelabeled with either radiometal and then conjugated to the antibody. Studies in human patients showed excellent ¹¹¹In single-photon emission computed tomography images of breast cancer lesions 24 h after injection.

Original language	English (US)
Journal	Cancer Research
Volume	55
Issue number	23 SUPPL.
State	Published - 1995

ASJC Scopus subject areas

Cancer Research
Oncology

Fingerprint Dive into the research topics of 'Prelabeling of chimeric monoclonal antibody L6 with<sup>90</sup>yttrium- and <sup>111</sup>indium-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy'. Together they form a unique fingerprint.

Cite this

Prelabeling of chimeric monoclonal antibody L6 with⁹⁰yttrium- and ¹¹¹indium-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy. / Li, Min; Meares, Claude F.; Salako, Qansy; Kukis, David L.; Zhong, Gao Ren; Miers, Laird; DeNardo, Sally J.

In: Cancer Research, Vol. 55, No. 23 SUPPL., 1995.

Research output: Contribution to journal › Article › peer-review

@article{0e11bf59d2f4403782a08415428e8951,

title = "Prelabeling of chimeric monoclonal antibody L6 with90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy",

abstract = " 90Y and 111In have been attached to chimeric monoclonal antibody L6 with a bifunctional chelating agent (DOTA-peptide isothiocyanate). The bifunctional chelating agent was prelabeled with either radiometal and then conjugated to the antibody. Studies in human patients showed excellent 111In single-photon emission computed tomography images of breast cancer lesions 24 h after injection.",

author = "Min Li and Meares, {Claude F.} and Qansy Salako and Kukis, {David L.} and Zhong, {Gao Ren} and Laird Miers and DeNardo, {Sally J.}",

year = "1995",

language = "English (US)",

volume = "55",

journal = "Journal of Cancer Research",

issn = "0099-7013",

publisher = "American Association for Cancer Research Inc.",

number = "23 SUPPL.",

}

TY - JOUR

T1 - Prelabeling of chimeric monoclonal antibody L6 with90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy

AU - Li, Min

AU - Meares, Claude F.

AU - Salako, Qansy

AU - Kukis, David L.

AU - Zhong, Gao Ren

AU - Miers, Laird

AU - DeNardo, Sally J.

PY - 1995

Y1 - 1995

N2 - 90Y and 111In have been attached to chimeric monoclonal antibody L6 with a bifunctional chelating agent (DOTA-peptide isothiocyanate). The bifunctional chelating agent was prelabeled with either radiometal and then conjugated to the antibody. Studies in human patients showed excellent 111In single-photon emission computed tomography images of breast cancer lesions 24 h after injection.

AB - 90Y and 111In have been attached to chimeric monoclonal antibody L6 with a bifunctional chelating agent (DOTA-peptide isothiocyanate). The bifunctional chelating agent was prelabeled with either radiometal and then conjugated to the antibody. Studies in human patients showed excellent 111In single-photon emission computed tomography images of breast cancer lesions 24 h after injection.

UR - http://www.scopus.com/inward/record.url?scp=0028875268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028875268&partnerID=8YFLogxK

M3 - Article

C2 - 7493335

AN - SCOPUS:0028875268

VL - 55

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23 SUPPL.

ER -